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Light has a profound effect on us.  We may not be conscious enough as 
regards the existences of many phototoxic substances and chemicals.  
A phototoxic substance is a chemical compound which becomes toxic 
when exposed to light.  Phototoxicity may be manifested in various 
ways. Proper use of sunscreens may play a vital role in the prevention 
of many such reactions. 
Introduction
The sun and the light that it emits are 
many times taken for granted, however 
light more precisely sunlight powers all 
life on earth, either directly or indirectly. 
Plants must have sunlight [or full-spectrum 
artificial light] to manufacture their food 
by photosynthesis. Plants, in turn, pass on 
their energy to the animals that consume 
them. Light is also essential for the survival 
of most animal species; even nocturnal 
animals require low-level light.  Animals 
that have evolved in total darkness such 
as troglobites[cave dwellers] or deep-
sea animals are often colourless, blind 
and cannot survive outside their natural 
environment. 
For all diurnal species (species that are 
active during the day), including humans, 
light is important for many reasons.  
Obviously, it is required for vision. For many 
species of animals, full-spectrum light is 
required for the conversion of cholesterol 
to vitamin D.  Light and its changing cycles 
– photoperiodicity; is used by animals to 
synchronize their biological clocks.   Light is 
indeed important for the psychological well 
being of animals.  
However the effect of light on humans 
is much more complex than we think.  It 
influences us in ways we many times do not 
expect or understand.  At least one study 
has suggested a direct correlation between 
higher rates of breast cancer in women 
and the night time brightness of their 
neighbourhoods.1  It is in fact postulated 
that this is at least partly due to a dramatic 
alteration in the lighted environment from 
a sun-based system to an electricity-based 
system. Increasingly, the natural dark 
period at night is being seriously eroded for 
the bulk of humanity.2 Based on the fact 
that light during the night can suppress 
melatonin, and also disrupt the circadian 
rhythm, it is proposed that increasing use of 
electricity to light the night accounts in part 
for the rising risk of breast cancer globally.3  
Light is nowadays being even considered as a 
public health issue.4
Photosensitivity and its epidemiology 
In the context of pharmacy, an 
important effect of light is what is 
termed as photosensitivity.  Drug-
induced photosensitivity is termed as an 
undesirable pharmacological reaction in 
light irradiation.5,6 Exposure to either the 
chemical or the light alone is not sufficient 
to induce the disease; however, when 
photoactivation of the chemical occurs, one 
or more cutaneous manifestations may arise. 
These include mainly either a phototoxic 
or a photoallergic reactions, but may also 
include a planus lichenoides reaction, 
pseudoporphyria, subacute cutaneous lupus 
erythematosus as well as hyperpigmentation, 
pigmentary changes or berloque dermatitis  
Photosensitivity reactions may result from 
systemic medications and topically applied 
compounds (Table 1). 
Wavelengths within the UV-A (320-400 
nm) range and, for certain compounds, 
within the visible range, are more likely 
to cause drug-induced photosensitivity 
reactions, although occasionally UV-B (290-
320 nm) can also be responsible for such 
effects. UV-B wavelengths are most efficient 
at causing sunburn and nonmelanoma skin 
cancer.9 
Photosensitivity eruptions typically occur 
in locations with prominent sun exposure 
such as in the face, extensor extremities, 
upper chest and back of neck.  Characteristic 
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Table 1. Some medications and other substances associated with photosensitivity7,8,6
Antibiotics  Ciprofloxacin and other quinolones, sulfonamides, dapsone,  
 griseofulvin.  Tetracyclines [especially demeclocycline; less  
 frequently doxycycline, oxytetracycline and tetracycline;  
 minocycline rarely]
Antihistamines Dimenhydrinate, cetirizine, loratidine
Anti-inflammatories  Ibuprofen, naproxen, piroxicam
[NSAIDS]
Anti-malarials Chloroquine and related compounds (such as    
 hydroxychloroquine), Sulfadoxine with 
 pyrimethamine [Fansidar®]
Cardiovascular drugs  ACE inhibitors, amiodarone, amlodipine, clopidogrel,   
 diltiazem, furosemide, losartan, nifedipine, statins,   
 thiazide diuretics, sotalol
CNS agents Carbamazepine, clomipramine, chlorpromazine,   
 phenotiazines, tricyclic antidepressants, 
 selegiline, zolpidem. 
 
Miscellaneous  Acetazolamide, oral contraceptives and oestrogen,   
 chemotherapy agents, ranitidine, sulfonylureas, tacrolimus 
Topical agents  Deodorants in soaps; perfumes; coal tar products 
Plants and herbs  Celery, giant hogweed, angelica, parsnip, fennel, 
 dill, anise, parsley, lime, lemon, rue, fig, mustard, 
 scurf pea, and chrysanthemums
 
Essential Oils  Fig leaf absolute oil; taget oil; vergena oil and verbena   
 absolute oil; bergamot oil; cumin oil; lime (expressed) oil;  
 angelica root oil; rue oil; opopanax oil; orange (bitter   
 expressed) oil; lemon (expressed) oil; grapefruit   
 (expressed) oil
Note: This list is NOT comprehensive.  Manufacturers’ package inserts should be consulted 
regarding potential photosensitivity of medications.  
sites of sparing include the upper eyelids, 
below the nose and chin, behind the 
earlobes and the finger-webs.  
Photosensitivity reactions can be 
classified according to the underlying 
mechanism.  They are the result of either 
phototoxicity or photoallergy.  In patients 
who present with photosensitivity, it is often 
difficult to differentiate phototoxic from 
photoallergic reactions. However, they have 
a number of distinguishing characteristics 
(Table 2). Phototoxic reactions represent the 
most common form, whereas photoallergic 
reactions are generally uncommon.6,10  
Phototoxic reactions may occur in almost 
any individual who received a high enough 
dose of the offending agent coupled with 
sufficient exposure to light irradiation.11 The 
occurrence of drug-induced phototoxicity 
reactions can thus be dependent on the 
concentration or amount of the sensitising 
agent and the amount of light exposure.11  
Phototoxic reactions
Phototoxic reactions are non-
immunologic in nature.  In these reactions 
the drug, after ingestion or topical 
application is believed to potentiate the 
solar energy by acting as a chromophore, 
causing absorption of ultraviolet light and 
causing damage to the skin tissue.5  
Acute phototoxicity often begins as an 
exaggerated sunburn reaction with erythema 
and oedema that occurs within minutes to 
hours of light exposure; vesicles and bullae 
may develop with severe reactions.9  The 
lesions often heal with hyperpigmentation, 
which resolves in a matter of weeks to 
months. Chronic phototoxicity may also 
appear as an exaggerated sunburn reaction. 
Lichenification often develops because of 
repeated rubbing and scratching of the 
photosensitive area. 
Distinguishing phototoxic reactions 
from photoallergic reactions strictly based 
on physical appearance of the lesions may 
be difficult.9   In contrast to photoallergic 
reactions drug-induced phototoxic reactions 
typically occur on first exposure to the 
drug, and they are often dose-related. 
5,9,10  Cases of drug-induced phototoxic 
reactions are associated with a much quicker 
onset relative to cases of drug-induced 
photoallergy.12  This could typically be 
within 30 minutes to several hours after 
exposure to UV light.  In general phototoxic 
reactions are less severe than photoallergic 
reactions and resemble a severe sunburn.12  
The skin damage that occurs in phototoxic 
reactions is typically confined to areas of 
exposed skin only.  Occasionally the nails 
may also be affected.  The phototoxic effect 
is a well-known phenomenon referred to as 
photooncholysis.7,12
A classic example of a medicine 
associated with phototoxicity [sometimes 
also with photoallergy] is amiodarone, which 
induces photosensitivity in 10-50% of the 
patients treated with this drug.6
However some reports even mention 
rates as high as 75%.13  As mentioned 
beforehand the development of phototoxicity 
is dose-dependent.  It is reported that an 
amiodarone-induced phototoxic reaction 
depends on a total dose of amiodarone of 
40g which is the minimal cumulative dose 
requirement. Under the regimens commonly 
used, photosensitivity can be expected 
after 4 months of continuous amiodarone 
treatment and appears to be unrelated to the 
skin type.  Phototoxicity gradually decreases 
and returns to normal between 4 and 12 
months after the withdrawal of amiodarone.6 
Photo-onycholysis, or separation of 
the distal nail plate from the nail bed, is 
another manifestation of phototoxicity. 
Photo-onycholysis has been reported with 
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Table 2. Differentiating characteristics of phototoxicity and photoallergy6,9,11,12
Characteristic  Phototoxicity  Photoallergy 
Frequency of occurrence Common  Uncommon
Mechanism Non-immune mediated Immune mediated [Type IV]
Onset  Immediate (minute to hours) after  May be delayed (hours to days) after exposure
 exposure to drug and sunlight to drug and sunlight
Distribution  Usually confined to exposed skin  May affect unexposed skin 
Potential for pigmentary changes High  Low
Dose dependency Yes No
 
Potential for cross-reactivity No  Yes
Potential for persistent light reaction No Yes 
   
Clinical characteristics  Exaggerated sunburn Dermatitis
the use of many systemic medications, 
including tetracycline, chloramphenicol, 
fluoroquinolones, oral contraceptives and 
mercaptopurine.  Photo-onycholysis may be 
the only manifestation of phototoxicity in 
individuals with heavily pigmented skin.9
Photoallergic reactions
Unlike phototoxic reactions drug-induced 
photoallergic reactions are the result of 
an immunologic response.  The proposed 
mechanism of photoallergic reactions is 
type IV cell-mediated hypersensitivity 
response.5  It is postulated that when 
UV light reacts with either the drug or 
the drug’s metabolites in the skin; this 
induces a structural change in the drug 
so that it behaves as a hapten.5,10. This 
hapten combines with proteins in the 
skin to form a hapten-protein complex [a 
compete antigen].  On subsequent exposure 
to the drug a hypersenistivity response is 
elicited.10. Once the patient is sensitised 
to the drug only minimal amounts of drug 
exposure are subsequently required to 
produce a photoallergic reaction.5  
Photoallergic reactions are thus the 
result of cell-mediated immunity and require 
an initial sensitization period – an acute, 
subacute or chronic eruption which is usually 
described as a papulovesicular, eczematous 
and intensely pruritic rash generally appears 
24 hours or more after exposure [onset can 
be anywhere from 24 to 48 hours to up to 
14 days after sun exposure] this due to the 
fact that photoallergic reactions involve 
the immune system and there is typically 
a delay between the time of exposure to 
the drug and the actual onset of the skin 
eruption.6,7,11  In general photoallergic 
reactions occurring in sensitised patients 
are not dose dependent.12  Generally 
photoallergic reactions involve mainly direct 
sun-exposed areas but in severe cases may 
also affect areas that are normally protected 
from UV light.6  Patients with photoallergic 
reactions should not take the offending drug 
again ever. 
 
Pigmentary changes and 
berloque dermatitis 
Other less common skin manifestations 
of phototoxicity include pigmentary 
changes. A blue-gray pigmentation is 
associated with several agents, including 
amiodarone, chlorpromazine, and some 
tricyclic antidepressants. Reactions 
to psoralen-containing botanicals 
(phytophotodermatitis) and drugs may 
resolve, with a brownish discoloration. 
Frequently, the pigmentary change is 
preceded by a typical sunburn reaction. If 
the reaction is not severe, some patients may 
not notice the erythema.
Pigmentary changes occur quite 
commonly as a manifestation of 
photosensitivity in patients receiving long-
term high-dose amiodarone therapy.13-18 
A blue-gray discoloration commonly 
develops on areas of skin that are subjected 
to unprotected light exposure due to 
deposition of amiodarone and its metabolites 
within the dermis. 3-16,18 Amiodarone-related 
hyperpigmentation develops after an average 
of 20 months of continuous amiodarone 
treatment and a minimal total dose of 160g 
amiodarone in about 8% of the patients, 
mainly of skin Type 1 - porcelain white skin. 
[Type 1 always burns and never tans. This 
type skin has the highest risk of skin cancer 
and wrinkles more readily than other types. 
Most Type 1 skin owners will have red or 
pale blonde hair, be blue-eyed and have 
freckles].13-18 
A specific form of hyperpigmentation is 
what is termed as berloque dermatitis.   The 
clinical presentation of berloque dermatitis 
may be classically divided into two phases. 
The initial acute inflammatory phase consists 
of erythema, oedema, pain, pruritus, and 
increase in skin temperature around the area 
of contact with the phototoxic agent. The 
second stage is hyperpigmentation of the 
lesion with patients typically presenting with 
small areas of redness or pigmentation of 
the skin, usually on sun-exposed areas.   A 
careful history may reveal use of a perfume 
or fragrance-containing product on the skin 
prior to a period of sun exposure, such as 
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sunbathing or a picnic. If untreated, the 
natural history of the disease is biphasic; 
the inflammatory lesions resolve in days 
to weeks, but the pigmentation may last 
months or even years.19
Bergapten, or 5-methoxypsoralen, is 
the photoactive component of bergamot oil 
from the bergamot lime (Citrus bergamia), 
which is a popular ingredient in perfumes 
and fragrances. Apart from its existence 
in cosmetics and other toiletries it may 
also be found in soap, household cleaners, 
detergents, air fresheners, and other related 
items.  Besides the bergamot lime, bergapten 
is a naturally occurring component of 
various other fruits and plants.  Examples of 
these are figs (Ficus carica), celery (Apium 
graveolens), lemon oil and Queen Anne’s lace 
(Ammi majus).19 
Pseudoporphyria 
Pseudoporphyria may occur with some 
medications, the most common of which is 
naproxen.9,20  Other medicines associated 
with pseudoporphyria are nalidixic acid, 
tetracycline, fuorsemide, bumetanide, 
amiodarone, cyclosporine, pyridoxine and 
dapsone.16  Frequent use of sun-tanning 
beds and chronic renal failure are other 
predisposing factors.
Pseudoporphyria is clinically 
characterized by increased skin fragility; 
erythema; and the appearance of tense 
bullae and erosions on sun-exposed skin, 
which are identical to those seen in patients 
with porphyria cutanea tarda.  However, 
a clinical pearl that may prove helpful in 
differentiating between pseudoporphyria 
and porphyria cutanea tarda is that 
the classic features of hypertrichosis, 
hyperpigmentation, and sclerodermoid 
changes found with porphyria cutanea tarda 
are unusual with pseudoporphyria.  The 
results of porphyrin studies are normal.21
The primary treatment of 
pseudoporphyria is to discontinue the 
offending agent whenever possible.   
Resolution of the clinical findings of drug-
induced pseudoporphyria may take many 
months.  Some patients may be left with 
permanent scarring.21
Lichenoid reactions
Lichenoid reactions that occur in a 
photodistribution are often difficult to 
distinguish from idiopathic lichen planus.22  
These reactions are characterized by 
violaceous or erythematous papules and 
plaques that sometimes have Wickham 
striae [whitish lines visible in the papules 
of lichen papules and other dermatoses,]  
Hydrochlorothiazide, hydroxychloroquine, 
enalapril, demeclocycline and captopril are 
known causes of drug-induced lichenoid 
reactions.
Lupus-like reactions 
Drug-induced photosensitivity reactions 
may also include lupus-like reactions.   
Such reactions may resemble subacute 
cutaneous lupus erythematosus because 
of their scaling, annular, and psoriasiform 
characteristics. 
Hydrochlorothiazide is the drug most 
frequently associated with this reaction but 
calcium channel blockers, ACE inhibitors, 
griseofulvin, and terbinafine are other agents 
that have been implicated.23,24 The rate of 
reaction is low for any of these agents. 
Photoaggravated tattoo reactions 
Photo-aggravated tattoo reactions 
are most commonly caused by yellow 
(cadmium sulfide) tattoo pigment. Oedema 
and erythema may develop upon exposure 
to sunlight. Although the mechanism is 
not clear, cadmium sulfide is the light-
sensitive material used in photoelectric cells; 
therefore, the reaction is believed to be 
phototoxic. 
Red tattoos [red dye is mercuric 
sulfide (cinnabar), sienna (ferric hydrate), 
sandalwood, brazilwood, organic pigments 
(aromatic azo compounds)]  have been 
associated with photo-aggravated tattoo 
reactions less frequently than yellow 
tattoos, and most likely, these reactions are 
related to the trace amounts of cadmium 
added to brighten the red pigment.  In 
contrast to hypersensitivity reactions to 
red tattoos, reactions to pigments used 
to create green [chromic oxide, lead 
chromate, phthalocyanine dyes], blue [cobalt 
aluminate] and black  [carbon (India ink), 
iron oxide, logwood] tattoos are much less 
common.25 
Treatment and prognosis of 
photosensitivity reactions 
The mainstays of treatment of 
drug-induced photosensitivity include 
identification and avoidance of the causative 
agent, the use of sun protection, and 
symptomatic relief.
Topical corticosteroids and cool 
compresses may alleviate drug-induced 
photosensitivity.  In severe cases systemic 
corticosteroids may be utilized. 
If sunscreens are not the cause of 
the photosensitivity, they should be used 
liberally.  The sun protection factor (SPF) 
may not be a reliable indicator of protection 
against drug-induced photosensitivity. 
The SPF refers to the degree of protection 
against sunlight-induced sunburn, primarily 
that caused by UV-B. Most drug-induced 
photosensitivity reactions are caused 
by wavelengths within the UV-A range. 
Therefore, sunscreens that absorb UV-A 
should be prescribed.  Sunscreens that 
contain avobenzone, titanium dioxide, and 
zinc oxide are more effective in blocking out 
UV-A radiation than sunscreens that contain 
other ingredients.9
In most patients, the prognosis is 
excellent once the offending agent is 
removed. However, complete resolution of 
the photosensitivity may take several weeks 
to months.  Occasionally, patients may have 
persistent light reactivity for which the 
prospects for resolution may be poor.10
Patient Education
Patients need to be counseled regarding 
the possible photosensitizing properties 
of both prescription and nonprescription 
medications. 
Most often, appropriate sun protection 
measures may prevent most drug-induced 
photosensitivity reactions.  Some practical 
information on the use of sunscreens may be 
found in Table 3
Conclusion
All health care professionals should 
make an effort to educate their patients 
and clients and raise the awareness to 
photosensitivity reactions as well as 
necessary prevention measures.  Health-
care professionals should also be aware on 
how best to use sunscreens in an effort to 
prevent as much as possible the occurrence 
of photosensitivty reactions
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Practice points7
•	 Sunscreens	should	be	applied	30	minutes	before	exposure	for	full	skin	exposure	and	
should be applied thickly for maximum water-resistance
•	 One	application	is	NOT	enough.		Experiments	show	a	time-dependent	decrease	in	
Sun-Protection Factor [SPF] within the first few hours after sunscreen application.  
Swimming abd perspiration also reduce the SPF value for many sunscreens
•	 Sun-screen	should	be	applied	after	sweating,	swimming,	toweling	and	hiking	
[clothing rubs it off exposed arms and legs].  Sunscreen should generally be re-
applied every 40-80 minutes
•	 Re-applying	sunscreen	during	the	day	does	NOT	extend	the	period	of	protection.		
[SPF 30 means a maximum of SPF 30 protection under ideal conditions and frequent 
reapplications
•	 The	SPF	is	the	amount	of	UV	radiation	required	to	cause	sunburn	on	skin	with	the	
sunscreen on, relative to the amount required without the sunscreen. So, wearing a 
sunscreen with SPF 30, one’s skin will not burn until it has been exposed to 30 times 
the amount of solar energy that would normally cause it to burn
•	 SPF	applies	to	UVB	rays	only.		It	does	NOT	apply	to	UVA.		An	SPF	30	product	with	
NO UVA screen will be less effective than a product with a lower SPF value which 
contains a UVA screen
•	 Sunscreens	should	be	applied	to	all	exposed	areas	of	the	skin,	including	overlooked	
areas such as back of the neck, tops of the feet [if in sandals] and the rims of the 
ears
•	 Multi-day	exposure	to	sunlight	increases	UV	sensitivity	on	subsequent	days	of	
exposure.  Higher SPF products must be used in such cases
•	 DEET-containing	insect	repellents	may	decrease	a	product’s	SPF	by	approximately	
30%.  Sunscreens can increase skin absorption of DEET
•	 Children	receive	50-80%	of	their	lifetime	exposure	to	UV	rays	by	the	time	they	are	18	
years old.  Sunscreens should thus be used early
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